Literature DB >> 1959987

Positive correlation between parity and incidence of thyroid cancer: new evidence based on complete Norwegian birth cohorts.

O Kravdal1, E Glattre, T Haldorsen.   

Abstract

We have examined the effect of parity on the incidence of thyroid cancer within a hazard model framework, using individual data on all (1.1 million) Norwegian women born 1935-1969. This unique data source was established by linking information from the Cancer Registry with maternity histories derived from the Central Population Register of Norway. The relative effects on the total incidence of thyroid cancer, net of age, place of residence and birth cohort, are 1.00 for the childless (arbitrarily chosen baseline group), 1.13 for parity 1, 1.30 for parity 2, 1.39 for parity 3 and 1.46 for parity 4+. The latter 3 figures are significantly higher than 1.00. The effects are larger for follicular carcinoma, and for this type of thyroid cancer there are also indications of a recent-pregnancy effect. Among women with 2 or more children, those who became pregnant less than 45 months previously have a higher cancer incidence than others at the same parity. Moreover, we have found that parity has virtually the same effect at all ages, in all birth cohorts and in both parts of the country. Age at first birth as well as the length of the interbirth interval appear to be unrelated to the thyroid-cancer risk. Our findings are consistent with previous case-control studies from other countries.

Entities:  

Mesh:

Year:  1991        PMID: 1959987     DOI: 10.1002/ijc.2910490606

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  The influence of parity on multinodular goiter prevalence in areas with moderate iodine deficiency.

Authors:  M Rotondi; F Sorvillo; G Mazziotti; S Balzano; S Iorio; A Savoia; M Piscopo; B Biondi; G Amato; C Carella
Journal:  J Endocrinol Invest       Date:  2002-05       Impact factor: 4.256

2.  Fetal growth and subsequent maternal risk of thyroid cancer.

Authors:  Casey Crump; Jan Sundquist; Weiva Sieh; Marilyn A Winkleby; Kristina Sundquist
Journal:  Int J Cancer       Date:  2015-10-05       Impact factor: 7.396

3.  Role of goiter and of menstrual and reproductive factors in thyroid cancer: a population-based case-control study in New Caledonia (South Pacific), a very high incidence area.

Authors:  Thérèse Truong; Laurent Orsi; Dominique Dubourdieu; Yannick Rougier; Denis Hémon; Pascal Guénel
Journal:  Am J Epidemiol       Date:  2005-06-01       Impact factor: 4.897

4.  Longchain serum fatty acids and risk of thyroid cancer: a population-based case-control study in Norway.

Authors:  J P Berg; E Glattre; T Haldorsen; A T Høstmark; I G Bay; A F Johansen; E Jellum
Journal:  Cancer Causes Control       Date:  1994-09       Impact factor: 2.506

5.  Parity and risk of thyroid cancer: a nested case-control study of a nationwide Swedish cohort.

Authors:  M R Galanti; M Lambe; A Ekbom; P Sparén; B Pettersson
Journal:  Cancer Causes Control       Date:  1995-01       Impact factor: 2.506

6.  Management of differentiated thyroid cancer in pregnancy.

Authors:  Syed Ali Imran; Murali Rajaraman
Journal:  J Thyroid Res       Date:  2011-05-25

7.  Reproductive factors and risk of thyroid cancer. A prospective study of 63,090 women from Norway.

Authors:  L A Akslen; S Nilssen; G Kvåle
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640

8.  Embolic suppurative thyroiditis with concurrent carcinoma in pregnancy: lessons in management through a case report.

Authors:  Manish M George; Jay Goswamy; Susannah E Penney
Journal:  Thyroid Res       Date:  2015-02-26

9.  Thyroid cancer epidemiology in England and Wales: time trends and geographical distribution.

Authors:  I dos Santos Silva; A J Swerdlow
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

10.  Second primary neoplasms in thyroid cancer patients.

Authors:  K Ishikawa; S Noguchi; K Tanaka; A Fukuda; T Hirohata
Journal:  Jpn J Cancer Res       Date:  1996-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.